ACRS - Aclaris Therapeutics GAAP EPS of -$0.37 misses by $0.01 revenue of $1.5M misses by $0.3M February, 24 2022 07:02 AM Aclaris Therapeutics Inc. Aclaris Therapeutics press release (NASDAQ:ACRS): Q4 GAAP EPS of -$0.37 misses by $0.01. Revenue of $1.5M (-5.1% Y/Y) misses by $0.3M. For further details see: Aclaris Therapeutics GAAP EPS of -$0.37 misses by $0.01, revenue of $1.5M misses by $0.3M